How to Localize Medical Device Labels and Instructions for Use for Vietnam Registration

Quick Answer

To localize medical device labels and instructions for use (IFUs) for Vietnam registration, a manufacturer should first confirm the target market, the product's risk classification, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labels and IFUs, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission so that unclear classification, incomplete documents or undefined authorization arrangements do not unnecessarily extend the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then decide whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Vietnam registration typically affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is driven only by the question of "which documents to submit," deficiencies and rework are likely to appear in model coverage, evidence-chain consistency, label claims and certificate control.

AIMEILI recommends addressing this question within a broader GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documentation from scratch in each country.

Prepared based on the AIMEILI regulatory practice question bank, the AIMEILI medical device international registration knowledge base and publicly available regulatory information. Specific projects should follow the latest requirements of the target country's regulatory authority and the actual documentation base of the product.

Published: 10 July 2026, 16:35  |  Last updated: 10 July 2026, 16:35

This article reviews the questions that companies should prioritize when working on international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content structure

• Key summary
• Applicable scenarios and core questions
• Registration assessment logic
• Documentation and evidence
• Common mistakes
• Company preparation checklist
• AIMEILI's perspective
• Common follow-up questions
• Further reading
• Scope and limitations

Key Summary

On the question of how to localize medical device labels and IFUs for Vietnam registration, companies should first confirm the target country, the product's risk class, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labels and IFUs, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission so that unclear classification, documentation or authorization arrangements do not prolong the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Vietnam registration usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance simultaneously. If the project is advanced only on the basis of "which documents must be submitted," deficiencies and rework are likely to arise in model coverage, evidence-chain consistency, label claims and certificate control. AIMEILI recommends placing this question within a broader GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than re-creating documentation on an ad hoc basis in each country.

Applicable Scenarios and Core Questions

Companies searching for guidance on how to localize medical device labels and IFUs for Vietnam registration are usually not looking for a conceptual explanation. They want to determine whether their existing documentation can support a Vietnam submission, whether a local agent or authorized representative is required, why timelines become extended, and which issues may affect their market launch plan. Behind this question there are usually several intertwined topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the procedure for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels and IFUs, and then adapt them to the regulatory requirements of each country.

Registration Assessment Logic

Companies should first confirm the intended purpose, mechanism of action, use scenario, mode of body contact, duration of use, whether the device is sterile or active, and whether it contains software or has IVD characteristics, and only then determine the risk class and submission pathway. If the pathway assessment is wrong, all subsequent translation, notarization, authorization, testing and supplementary submissions will be directed incorrectly.

For a Vietnam project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who handles regulatory communication, who manages importation and post-market events, who triggers changes, and who maintains renewal documentation. If these matters are addressed only vaguely in a commercial contract, market control can easily be compromised later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended purpose, basis for risk classification, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labels and IFUs, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Mistakes

The most common problem is treating registration as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without reorganizing the evidence according to the Vietnam pathway.
• Listing too many models and specifications while test reports, clinical evidence or label coverage are insufficient.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistencies between labels, IFUs, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan for multi-country documentation reuse in advance, resulting in duplicated preparation work in each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix and intended purpose statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language IFUs.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be re-tested, translated, notarized or supported by additional declarations.

AIMEILI's Perspective

AIMEILI advises companies not to view Vietnam registration as a one-off document submission, but to manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable, and more conducive to subsequent changes and certificate renewals than filling documentation gaps country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated deficiency responses, agent communication issues and post-market maintenance problems, even if the documentation appears extensive.

Common Follow-up Questions

Can documentation prepared in China be used directly for Vietnam registration?

Chinese documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labeling, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after confirming the target market and the product list. The earlier the gap assessment is completed, the earlier companies can arrange supplementary testing, translation, label adjustments and agent selection.

Why does the choice of local agent affect registration quality?

The local agent is typically involved in registration communication, changes, renewals and post-market event handling. Unclear responsibilities and rights can affect certificate control and the stability of the subsequent market.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project register that manages the product list, model and specification matrix, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the market launch plan.

Companies that already have registrations in several countries should also establish an evidence reuse matrix, specifying which documents can serve as core evidence and which must be reissued or supported by additional explanations in accordance with national requirements. Labels and IFUs, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the device being submitted, or if the manufacturing address, model and specification, or IFU version does not match the test reports, the company may be asked for supplementary explanations even if it has prepared a large volume of documentation.

Companies should establish an evidence consistency checklist before submission, mapping the product name, model and specification, intended purpose, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version and quality system certificate item by item. Although this appears basic, it can significantly reduce the likelihood of deficiency letters, particularly for projects involving simultaneous submissions in several GHWP member states or for multiple product families.

Localization Transfer and Agent Responsibilities

Vietnam registration projects usually involve arrangements with a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the subsequent market.

Labels, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization transfer is to convert reusable evidence into a submission structure acceptable in the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance, so that when a manufacturing address change, model extension, IFU update or agent replacement occurs, the certificate and market sales can become disconnected.

AIMEILI recommends managing this issue within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of doing so is not only greater efficiency in individual country registrations; more importantly, it allows companies to build a replicable compliance capability for going global and reduces the cost of starting from scratch each time they enter a new market.

Further Reading

• Previous: How should the technical file for Vietnam medical device registration be organized?
• Next: How should clinical evaluation documentation for Vietnam medical device registration be prepared?
• Recommended: How should registration documentation for Malaysia medical device registration be prepared?
• Recommended: How should product classification for Malaysia medical device registration be determined?
• Recommended: How should the technical file for Malaysia medical device registration be organized?
• Recommended: How should labels and IFUs be localized for Malaysia medical device registration?
• Recommended: How should clinical evaluation documentation for Malaysia medical device registration be prepared?
• Recommended: Can test reports be reused for Malaysia medical device registration?
• Back to the FAQ Center
• News and insights
• Contact AIMEILI

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Sourcing principle: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.